Corteva (NYSE:CTVA – Free Report) had its price objective increased by Oppenheimer from $89.00 to $95.00 in a report issued on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.
A number of other analysts also recently commented on the stock. Berenberg Bank boosted their price objective on shares of Corteva from $68.00 to $78.00 and gave the stock a “hold” rating in a report on Thursday, March 26th. Royal Bank Of Canada lifted their price target on shares of Corteva from $97.00 to $103.00 and gave the company an “outperform” rating in a research report on Tuesday. Mizuho boosted their price target on Corteva from $96.00 to $97.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. UBS Group lowered their price target on Corteva from $90.00 to $86.00 and set a “neutral” rating on the stock in a report on Tuesday, June 9th. Finally, Argus raised their price objective on Corteva from $80.00 to $91.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, Corteva presently has a consensus rating of “Moderate Buy” and an average target price of $90.19.
Read Our Latest Stock Analysis on Corteva
Corteva Stock Performance
Corteva (NYSE:CTVA – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.32. The firm had revenue of $4.91 billion during the quarter, compared to analysts’ expectations of $4.64 billion. Corteva had a return on equity of 9.95% and a net margin of 6.50%.Corteva’s revenue was up 11.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.13 earnings per share. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, equities analysts forecast that Corteva will post 3.75 EPS for the current year.
Corteva Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, June 15th. Shareholders of record on Monday, June 1st were paid a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Monday, June 1st. Corteva’s dividend payout ratio is currently 42.35%.
Institutional Trading of Corteva
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTVA. JPL Wealth Management LLC purchased a new stake in Corteva in the third quarter valued at approximately $25,000. Garton & Associates Financial Advisors LLC purchased a new stake in shares of Corteva during the 4th quarter valued at $27,000. Bank of Jackson Hole Trust acquired a new stake in shares of Corteva during the 4th quarter worth $28,000. Cornerstone Financial Management LLC purchased a new position in shares of Corteva in the 4th quarter worth $29,000. Finally, Elevation Wealth Partners LLC boosted its holdings in Corteva by 334.6% in the second quarter. Elevation Wealth Partners LLC now owns 339 shares of the company’s stock valued at $29,000 after acquiring an additional 261 shares during the last quarter. Hedge funds and other institutional investors own 81.54% of the company’s stock.
Corteva Company Profile
Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.
Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.
Featured Articles
- Five stocks we like better than Corteva
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.
